Cytosorbents Corp (NASDAQ:CTSO) – Analysts at Dawson James increased their FY2021 EPS estimates for Cytosorbents in a research report issued to clients and investors on Monday, August 12th. Dawson James analyst J. Kolbert now forecasts that the medical research company will post earnings per share of $0.46 for the year, up from their prior estimate of $0.43. Dawson James also issued estimates for Cytosorbents’ FY2022 earnings at $1.19 EPS and FY2023 earnings at $2.24 EPS.
Cytosorbents (NASDAQ:CTSO) last released its earnings results on Tuesday, August 6th. The medical research company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.03. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.53 million. Cytosorbents had a negative net margin of 72.43% and a negative return on equity of 105.97%.
A number of other analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Cytosorbents in a research report on Wednesday, August 7th. B. Riley set a $12.00 price target on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Friday, July 19th. ValuEngine cut shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, Maxim Group set a $14.00 price target on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $13.67.
NASDAQ:CTSO opened at $4.77 on Wednesday. The firm’s 50-day moving average price is $6.65 and its 200-day moving average price is $7.13. The company has a market capitalization of $173.47 million, a PE ratio of -8.52 and a beta of 1.50. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.21 and a quick ratio of 3.00. Cytosorbents has a 1-year low of $3.68 and a 1-year high of $14.95.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Cytosorbents by 1.1% in the 2nd quarter. BlackRock Inc. now owns 2,008,123 shares of the medical research company’s stock worth $13,274,000 after purchasing an additional 21,791 shares in the last quarter. Vanguard Group Inc. raised its position in Cytosorbents by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,375,707 shares of the medical research company’s stock valued at $9,094,000 after purchasing an additional 6,698 shares in the last quarter. Skylands Capital LLC raised its position in Cytosorbents by 7.0% in the 2nd quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock valued at $4,499,000 after purchasing an additional 44,550 shares in the last quarter. Northern Trust Corp raised its position in Cytosorbents by 1.7% in the 2nd quarter. Northern Trust Corp now owns 354,447 shares of the medical research company’s stock valued at $2,343,000 after purchasing an additional 5,852 shares in the last quarter. Finally, Sargent Investment Group LLC raised its position in Cytosorbents by 15.9% in the 2nd quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock valued at $2,207,000 after purchasing an additional 45,840 shares in the last quarter. Institutional investors own 26.35% of the company’s stock.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Read More: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.